{
    "nct_id": "NCT03340766",
    "official_title": "A Phase 1b Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adult Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
    "inclusion_criteria": "* Have histologically confirmed diffuse large B-cell lymphoma that is either:\n* Refractory after at least one regimen of systemic chemotherapy and/or targeted therapy, or\n* In first or later relapse if have received at least 2 systemic regimens since time of diagnosis, or\n* Relapsed post-autologous or allogeneic hematopoietic stem cell transplantation (HSCT) with adequate organ function after proximity to transplantation time exclusions\n* Have measurable disease\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n* Life expectancy of ≥ 12 weeks in the opinion of the Investigator\n* Biopsy proven DLBCL (biopsy proven at least at primary diagnosis of DLBCL)\n\nOther Inclusion Criteria May Apply\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Richter's transformation (DLBCL arising in the setting of prior chronic lymphocytic leukemia) or primary mediastinal B cell lymphoma (PMBCL)\n* History or presence of clinically relevant central nervous system pathology such as epilepsy, paresis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.\n* Has a diagnosis of immunodeficiency or has received systemic steroid therapy (in excess of 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of protocol specified therapy.\n* Has undergone prior allogeneic HSCT:\n* within the last 5 years OR\n* greater than 5 years ago but has active graft versus host disease (GvHD) requiring systemic treatment.\n* Has received autologous HSCT within 6 weeks prior to start of treatment.\n\nOther Exclusion Criteria May Apply.",
    "miscellaneous_criteria": ""
}